Develops RNA interference (RNAi) therapies for cardiovascular, metabolic, and other diseases, focusing on gene silencing technology.
Silence Therapeutics plc is a pioneering biotechnology company dedicated to advancing the field of ribonucleic acid (RNA) therapeutics across a spectrum of medical specialties including hematology, cardiovascular diseases, and rare metabolic conditions. Central to its innovation is the mRNAi GalNAc Oligonucleotide Discovery platform, engineered to precisely target disease-associated genes within the liver. By leveraging short interfering RNA (siRNA) molecules, Silence Therapeutics harnesses the natural RNA interference mechanism to degrade messenger RNA encoding specific disease-associated proteins, offering a promising approach to treating various debilitating disorders.
The company's robust pipeline features several promising product candidates. Among these are SLN360, currently undergoing Phase I clinical trials for treating cardiovascular disease characterized by elevated lipoprotein levels. Additionally, SLN124 is in Phase I trials for non-transfusion dependent thalassemia and myelodysplastic syndrome, with further exploration for polycythemia vera treatment. Silence Therapeutics plc maintains strategic collaborations to enhance its therapeutic capabilities. Collaborative agreements with AstraZeneca PLC focus on developing small interfering RNA therapies for cardiovascular, renal, metabolic, and respiratory diseases, while its partnership with Mallinckrodt Pharma IP Trading DAC aims to develop RNAi drug targets to mitigate complement-mediated disorders. The company also collaborates with Hansoh Pharmaceutical Group Company Limited to advance siRNA therapies targeting undisclosed conditions using Silence's mRNAi GOLD platform.
Established as SR Pharma plc and rebranded as Silence Therapeutics plc in May 2007, the company is headquartered in London, United Kingdom. With a commitment to scientific excellence and therapeutic innovation, Silence Therapeutics plc continues to drive advancements in RNA-based therapies, poised to redefine treatment paradigms and improve outcomes for patients worldwide.